Browse the evidence

Rapamycin inhibits cell cycle arrest markers (p16, p21) and activates autophagy through an Nrf2-dependent mechanism.

To benefit from rapamycin's ability to stop cells from stopping dividing (cell cycle arrest), your body's Nrf2 antioxidant pathway must be functional.

Chronic ingestion of a western diet (high glucose and free fatty acids) causes endothelial stress and platelet hyperactivity, which precedes and drives systemic metabolic inflammation and insulin resistance.

Focus on the quality and combination of your meals rather than just calorie counting or sugar avoidance. High-fat and high-carb meals can both trigger acute blood vessel stress. Prioritize whole foods that minimize rapid spikes in blood glucose and free fatty acids to protect your endothelial health and prevent the inflammation that leads to insulin resistance.

Pioglitazone (PPAR-gamma agonist) improves histological features of NASH but is limited by problematic weight gain and is not widely adopted.

Pioglitazone can improve liver histology in NASH patients (34% vs 19% placebo), but it causes weight gain and is not widely used. It is considered only when lifestyle changes fail and other options are not suitable.

In the presence of a high-fat diet, fructose supplementation causes pronounced obesity, glucose intolerance, and hepatic insulin resistance, whereas glucose supplementation does not cause these metabolic deficits despite similar caloric intake.

If you are eating a high-fat diet, the type of sugar you consume matters significantly. Fructose (found in high-fructose corn syrup and table sugar) promotes obesity and insulin resistance, whereas glucose does not have the same negative impact on insulin signaling under these conditions. To mitigate metabolic risk, prioritize reducing fructose intake, especially when dietary fat is high.

Fructose uniquely upregulates the transcription factor SREBP1c and downstream fatty acid synthesis genes, leading to reduced liver insulin signaling, whereas glucose upregulates ChREBP and triglyceride synthesis without impairing insulin signaling.

Understanding how different sugars affect your liver can help you make better choices. Fructose drives fat production and insulin resistance through specific genetic pathways (SREBP1c), while glucose may actually support insulin sensitivity. If you consume high-fat meals, minimizing fructose (soda, candy) is more critical for metabolic health than avoiding glucose sources.

Mitochondrial dysfunction, characterized by impaired oxidative capacity and increased reactive oxygen species (ROS), promotes insulin resistance in skeletal muscle by causing the accumulation of lipotoxic lipid intermediates (diacylglycerol and ceramide) that inhibit insulin signaling.

For those with insulin resistance or T2DM, focusing on interventions that support mitochondrial health (like exercise which upregulates PGC-1α) may be more effective than focusing solely on caloric restriction. The paper suggests that boosting mitochondrial function can improve insulin sensitivity, potentially by reducing toxic lipid buildup in muscles.

Obesity-induced adipose tissue hypertrophy triggers a proinflammatory state (via TNF-α, IL-6, MCP-1, and reduced adiponectin) that directly causes endothelial dysfunction by disrupting the balance of vasodilators (NO) and vasoconstrictors, initiating atherosclerosis and cardiovascular disease.

Excess body fat is not just stored energy; it acts as an active organ that releases inflammatory chemicals (like TNF-α and IL-6) and reduces protective ones (adiponectin). This chemical imbalance damages the inner lining of your blood vessels (endothelium), leading to stiffness, plaque buildup, and heart disease risk. Managing weight and inflammation is critical to protecting your vascular health.

In skeletal muscle, the accumulation of lipid intermediates such as diacylglycerol (DAG) and ceramides directly impairs insulin-stimulated glucose uptake by activating serine/threonine kinases that inhibit the insulin receptor substrate-1 (IRS-1).

If you have insulin resistance, simply reducing total body fat is the standard approach, but understanding that specific toxic lipid byproducts (like DAGs) are the direct cause helps explain why some lean individuals or athletes might have different metabolic profiles. Focus on improving metabolic flexibility through exercise, which helps clear these toxic intermediates.

Perilipin 2 (PLIN2) and Perilipin 5 (PLIN5) overexpression in skeletal muscle can protect against lipotoxicity and improve insulin signaling by sequestering fatty acids into lipid droplets, thereby reducing toxic lipid intermediates like DAG and ceramides.

Endurance training and metabolic health can upregulate protective proteins like PLIN5, which help store fatty acids safely in lipid droplets. This prevents them from turning into toxic byproducts that block insulin action. Prioritize exercises that improve metabolic flexibility.

Targeting de novo lipogenesis (DNL) via ACC inhibitors (e.g., GS-0976, MK-4074) significantly reduces hepatic steatosis and DNL in patients with NASH.

ACC inhibitors like GS-0976 are being tested to directly reduce liver fat production. In trials, 20mg daily for 12 weeks reduced liver fat by 29%, significantly better than placebo. This is a pharmacological option for those who may not achieve sufficient weight loss through lifestyle alone.

Estrogen (17β-estradiol) improves insulin sensitivity and suppresses hepatic gluconeogenesis by activating the ERα-PI3K-Akt-Foxo1 signaling pathway, thereby reducing fasting blood glucose levels.

In preclinical models, estrogen improves blood sugar control by telling the liver to stop producing excess glucose. This happens through a specific signaling pathway involving ERα and Foxo1. This suggests that maintaining healthy estrogen levels or targeting this specific liver pathway could be a strategy for managing glucose metabolism, particularly in postmenopausal women or those with estrogen deficiency.

Obese visceral fat inflammation is an initially protective adaptive response to restore metabolic homeostasis, but becomes detrimental when structural damage and senescence trigger chronic immune infiltration.

Understand that inflammation in fat tissue is not just 'damage' but a complex signal. In the early stages of weight gain, it helps your body adapt to storing more energy. However, if this stress continues, the system breaks down, leading to structural damage and chronic disease. The goal is not to blindly suppress inflammation but to address the root cause: excess nutrient influx and adipocyte overload.

Adipocyte hypertrophy and subsequent endoplasmic reticulum stress trigger a pro-inflammatory response (metaflammation) that initially preserves metabolic control by promoting lipolysis and tissue remodeling.

As fat cells grow larger, they become stressed and send out signals to break down fat and remodel tissue. This is a natural attempt to manage excess energy. If this system works, you may remain metabolically healthy despite being overweight.

Chronic structural damage in visceral fat, characterized by adipocyte death and senescence, shifts inflammation from protective to detrimental by recruiting circulating immune cells and causing fibrosis.

When fat cells die or become senescent, they release signals that attract immune cells, leading to chronic inflammation and scarring (fibrosis). This is the stage where metabolic health typically declines.

SGLT-2 inhibitor monotherapy produces only moderate weight loss (1.5–2 kg) in obesity because it triggers counter-regulatory mechanisms that increase appetite and energy intake, offsetting the caloric deficit from glucosuria.

If you use an SGLT-2 inhibitor (like Jardiance or Farxiga) for weight loss, expect a modest drop of 1.5–2 kg. Your body will likely try to counteract this by making you hungrier. To get significant weight loss, this medication is rarely enough on its own; it works best when combined with drugs that suppress appetite (like GLP-1 agonists) or lifestyle changes that actively manage hunger.

Genetic variants associated with restless legs syndrome (RLS) also influence sleep duration, quality, and timing.

If you have RLS, addressing it may improve overall sleep metrics.

Single-dose AAV-mediated liver-specific FGF21 gene therapy reverses diet-induced obesity, hepatic steatosis, and insulin resistance in mice through sustained elevation of circulating FGF21 and increased energy expenditure.

This research suggests that a single injection of a viral vector delivering the FGF21 gene to the liver can sustainably reverse obesity and insulin resistance in mice by boosting energy expenditure. While promising, this is preclinical data; human applications are not yet established.

Menopausal hormone therapy (MHT) using estrogens delays the onset of type 2 diabetes in postmenopausal women, primarily by improving insulin sensitivity and glucose effectiveness, though it is not FDA-approved for this indication due to risk-benefit complexity.

If you are postmenopausal and suffering from symptoms, MHT may help prevent type 2 diabetes by improving how your body handles insulin and glucose. However, it is not prescribed solely for diabetes prevention due to other health risks. Discuss with your doctor if the benefits for your specific symptoms outweigh the risks, especially if you are at higher risk for diabetes.

Metformin reduces hepatic glucose production primarily by inhibiting fructose-1,6-bisphosphatase (FBP1) via AMP-mediated allosteric inhibition, rather than solely through AMPK activation.

Metformin lowers blood sugar partly by directly inhibiting an enzyme (FBP1) in the liver that makes glucose, triggered by changes in cellular energy (AMP). This happens alongside its known effects on AMPK. For patients, this means metformin is effective through multiple pathways, which may explain its broad utility in type 2 diabetes management.

Aging causes a redistribution of lipids from subcutaneous to visceral adipose tissue, leading to ectopic lipid storage, insulin resistance, and chronic low-grade systemic inflammation.

As you age, your body naturally shifts fat storage from under the skin to around your organs, which increases health risks. This shift is driven by hormonal changes and reduced activity of brown fat. While you can't stop aging, you can counteract these effects through regular exercise, weight management, and potentially medical interventions that improve insulin sensitivity, helping to maintain metabolic health and quality of life.

Aging is associated with an increase in pro-inflammatory adipokines and a decline in anti-inflammatory adipokines, contributing to a chronic state of low-grade systemic inflammation known as 'inflammaging'.

As you age, your fat cells release more inflammatory signals and fewer protective ones, leading to chronic low-grade inflammation. This 'inflammaging' increases the risk of diseases like diabetes and heart disease. Managing weight and staying active can help modulate these inflammatory signals.

Mitochondrial dysfunction is a necessary driver of the Senescence-Associated Secretory Phenotype (SASP), as evidenced by the elimination of SASP in cells devoid of mitochondria, while irreversible cell cycle arrest persists.

Aging and age-related inflammation are driven by dysfunctional mitochondria producing the SASP. Interventions that target mitochondrial health (e.g., senolytics, senostatics like rapamycin or metformin) may reduce this inflammatory burden. Focus on strategies that support mitochondrial quality control, such as exercise and metabolic health, rather than just energy output.

Metabolic syndrome (MetS) is independently associated with a higher risk of major cardiovascular events, cardiovascular mortality, and all-cause mortality, advancing the onset of these risks by approximately 3.2 years.

Having metabolic syndrome significantly increases your risk of heart attack, stroke, and early death, advancing the onset of these risks by over 3 years. However, managing individual components like high blood pressure, high triglycerides, or low HDL cholesterol is just as effective for risk reduction as treating the syndrome as a whole unit. Focus on controlling these specific metrics.

Metabolic syndrome is NOT associated with a higher risk of myocardial infarction or stroke, although individual components like elevated blood pressure, reduced HDL, and elevated triglycerides are.

Having metabolic syndrome does not necessarily increase your risk of heart attack or stroke, but managing individual components like high blood pressure, low HDL cholesterol, and high triglycerides does reduce this risk. Focus on controlling these specific markers.